Clinical Research Directory

Inclusion Criteria Signed written informed consent prior to enrollment Age ≥ 18 years ECOG PS score 0-1 Newly diagnosed T1c N1-2 or T2-3 N0-2 breast cancer Triple-negative breast cancer with PD-L1 CPS \< 10 Hemoglobin ≥ 10.0 g/dl, neutrophils ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L BUN ≤ 1.5 × upper limit of normal (ULN), creatinine ≤ 1.5 × ULN Serum bilirubin ≤ 1.5 × ULN, alkaline phosphatase (AKP), AST, and ALT ≤ 2.5 × ULN Women of childbearing potential must be willing to use contraception during the study Negative serum or urine pregnancy test within 7 days prior to treatment Exclusion Criteria Occult breast cancer Bilateral breast cancer Breast tumor unsuitable for SBRT Unable to undergo MRI scanning History of other malignancies that may affect survival Active autoimmune disease or history of autoimmune disease Current use of immunosuppressants or systemic steroids (within 2 weeks prior to enrollment) Known allergy to any component of the investigational drugs Uncontrolled cardiac symptoms or diseases Active infection or unexplained fever \> 38.5°C during screening/before first dose Other factors likely to cause early study termination (e.g., serious concurrent illnesses, significant lab abnormalities, or social/family circumstances affecting safety/data collection)